UPDATE: CANCELLED DUE TO GOVERNMENT SHUTDOWN
David Goldman, M.D.: January 23, 2018
"Genetics of Addiction: How Many Genes?”
William K. Warren, Jr. Frontiers in Neuroscience Lecture
Laureate Psychiatric Clinic and Hospital Conference Center
11:00am - 11:45 am Registration and Lunch, lunch stops being served at 11:45 - no exceptions
12:00pm - 1:00pm Program
Dr. David Goldman has been Chief of the Laboratory of Neurogenetics since 1991 and is Acting Clinical Director of NIAAA. Dr. Goldman graduated cum laude from Yale University and magna cum laude from the University of Texas Medical Branch, Galveston where he was also a Resident in Psychiatry. He joined NIAAA in 1979, was an NIMH Clinical Associate 1980-1984, and rejoined NIAAA in 1985. He is a Fellow of the American College of Neuropsychopharmacology. He has won the NIH Director’s Award twice, and the James Isaacson Research Award of the International Society for Biological Research on Alcoholism. Dr. Goldman is author of “Our Genes, Our Choices,” which won The British Medical Association top prize. Throughout his career, Dr. Goldman has focused on identifying genes that influence vulnerability to alcoholism, other addictions and other psychiatric diseases. He has authored over 400 papers, including several of the first “imaging genetics” studies in which genes were shown to alter brain function. He and his group use genomic methods, including sequencing, genome wide association, epigenetic studies and gene-based measurement of ancestry. He has discovered inherited variants that alter molecular function and traced the effects of these variants through to complex behaviors in both humans and animal models. Several, for example a variant of catechol-O-methyltransferase, which he has named a “warrior/worrier gene” alters stress response and emotion but also cognition, and the gene effects are context-dependent and stronger on molecules and intermediate brain functions. Several of Dr. Goldman’s studies involve the use of well-defined founder populations, including Finland and Native American Indian communities. He discovered an HTR2B “to be or not to be” stop codon that can lead to severe impulsivity. This strongly functional variant of a neurotransmitter receptor is population specific, being common in Finns, and absent in others. Dr. Goldman’s studies have also taken advantage of the ability to control genetic and environmental factors in animal models, both for gene discovery and for validation of gene effects.
Learning objectives:
David Goldman, M.D.: January 23, 2018
"Genetics of Addiction: How Many Genes?”
William K. Warren, Jr. Frontiers in Neuroscience Lecture
Laureate Psychiatric Clinic and Hospital Conference Center
11:00am - 11:45 am Registration and Lunch, lunch stops being served at 11:45 - no exceptions
12:00pm - 1:00pm Program
Dr. David Goldman has been Chief of the Laboratory of Neurogenetics since 1991 and is Acting Clinical Director of NIAAA. Dr. Goldman graduated cum laude from Yale University and magna cum laude from the University of Texas Medical Branch, Galveston where he was also a Resident in Psychiatry. He joined NIAAA in 1979, was an NIMH Clinical Associate 1980-1984, and rejoined NIAAA in 1985. He is a Fellow of the American College of Neuropsychopharmacology. He has won the NIH Director’s Award twice, and the James Isaacson Research Award of the International Society for Biological Research on Alcoholism. Dr. Goldman is author of “Our Genes, Our Choices,” which won The British Medical Association top prize. Throughout his career, Dr. Goldman has focused on identifying genes that influence vulnerability to alcoholism, other addictions and other psychiatric diseases. He has authored over 400 papers, including several of the first “imaging genetics” studies in which genes were shown to alter brain function. He and his group use genomic methods, including sequencing, genome wide association, epigenetic studies and gene-based measurement of ancestry. He has discovered inherited variants that alter molecular function and traced the effects of these variants through to complex behaviors in both humans and animal models. Several, for example a variant of catechol-O-methyltransferase, which he has named a “warrior/worrier gene” alters stress response and emotion but also cognition, and the gene effects are context-dependent and stronger on molecules and intermediate brain functions. Several of Dr. Goldman’s studies involve the use of well-defined founder populations, including Finland and Native American Indian communities. He discovered an HTR2B “to be or not to be” stop codon that can lead to severe impulsivity. This strongly functional variant of a neurotransmitter receptor is population specific, being common in Finns, and absent in others. Dr. Goldman’s studies have also taken advantage of the ability to control genetic and environmental factors in animal models, both for gene discovery and for validation of gene effects.
Learning objectives:
- Understand heritability of addiction.
- Define environmentality of addiction.
- Know some genes influencing addictions.
RSS Feed